Scientific publications
GeNeuro’s science is based on more than 25 years of research, performed internally and in collaboration with renowned academic groups.
A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env
Clinical Therapeutics, July 13, 2019
https://www.clinicaltherapeutics.com/article/S0149-2918(19)30296-6/pdf
ECTRIMS 2109 – Neuroprotective effects of temelimab in relapsing-remitting MS patients extend to 96 weeks
Phase IIb safety and efficacy data on temelimab at week 96 from the ANGEL-MS study
Neural Cell Responses Upon Exposure to Human Endogenous Retroviruses
Frontiers in Genetics, July 11, 2019
https://www.frontiersin.org/articles/10.3389/fgene.2019.00655/full
Variation in proviral content among human genomes mediated by LTR recombination
Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination
Glia, November 14, 2018
https://geneuro.ch/data/news/2018-11-Go-ttle-et-al.-GLIA.pdf
GNbAC1 shows efficacy on MRI measures of neurodegeneration in relapsing-remitting MS patients over 48 weeks
Robert Glanzman at the 26th Annual Meeting of the European Charcot Foundation (November 2018) in Baveno, Italy